CD8A and cancer: The engagement of CD3 (part of the T-cell receptor) induces both proliferation of CD4 and CD8 T-cells and cytotoxic activity by CD8 and in part CD4 cells against the target, to eliminate cancer cells without genetic alteration of the T cells or need for ex vivo expansion/manipulation, providing off-the-shelf immuno-oncotherapy (56, 57).